User:Mjelliott1975/Narrow Specific Kinase Inhibitors (NSKIs)
 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Narrow Spectrum Kinase Inhibitors (NSKIs) are similar to protein kinase inhibitors except that they target a far narrower range of kinases, which act as key signaling molecules in inflammatory cells.
The inhibition of narrow specific kinase combinations drives potent inhibitory effects in a wide range of cells[1], a quality which makes NSKIs highly effective in treating inflammatory illness[2].
Due to these properties NSKIs have a range of applications in modulating immune system activity both innate and adaptive[2].
The body's mucosal surface cells retain NSKIs effectively after administration, meaning that they remain active on a longer basis than typical protein kinase inhibitors without the need for re-administration[3]. The residual presence of the compound in the circulatory system is lower than with other inhibitors, meaning that the use of NSKIs is safer and carries less risk of negative side effects than similar protein kinase molecules[4]. As a result NSKIs are being viewed by many in the life sciences industry as a potential replacement for traditional protein kinase inhibitors[5].
Topical/local delivery of NSKIs results in[6]:
• Improved efficacy in cellular and in vivo inflammation models compared to selective kinase inhibitors.
• Efficacy equivalent to or better than cyclosporine, corticosteroids and anti-TNFa in animal models of inflammatory disease.
• Efficacy in steroid-insensitive inflammation in vitro and in vivo.
The development of NSKIs has revolutionary implications for the treatment of cancer and could bring about the end of debilitating side effects for patients undergoing chemotherapy[7].
References[edit]
- ^ "Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective - GaBI Journal". gabi-journal.net. Retrieved 2015-10-22.
- ^ a b To, Wing S; Aungier, Susan R; Cartwright, Alison J; Ito, Kazuhiro; Midwood, Kim S (2015-08-01). "Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells". British Journal of Pharmacology. 172 (15): 3805–3816. doi:10.1111/bph.13170. ISSN 1476-5381. PMC 4523337. PMID 25891413.
- ^ Contoli, Marco; Ito, Kazuhiro; Poletti, Donatella; Pastore, Antonio; Papi, Alberto (2011-09-01). "Novel narrow spectrum kinase inhibitors inhibit rhinovirus replication via enhancement of interferon expression in nasal epithelial cells of atopic and non-atopic patients". European Respiratory Journal. 38 (Suppl 55): p3495. ISSN 0903-1936.
{{cite journal}}:|pages=has extra text (help) - ^ LoRusso, Patricia M.; Eder, Joseph Paul (2008-07-01). "Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology". Expert Opinion on Investigational Drugs. 17 (7): 1013–1028. doi:10.1517/13543784.17.7.1013. ISSN 1354-3784. PMID 18549338.
- ^ Guha, Malini (December 2012). "Cyclin-dependent kinase inhibitors move into Phase III" (PDF). Nature Reviews: Drug Discovery. Retrieved 22 October 2015.
- ^ "TopiVert Pharma Limited". www.topivert.com. Retrieved 2015-10-22.
- ^ Arora, Amit; Scholar, Eric M. (2005-12-01). "Role of Tyrosine Kinase Inhibitors in Cancer Therapy". Journal of Pharmacology and Experimental Therapeutics. 315 (3): 971–979. doi:10.1124/jpet.105.084145. ISSN 1521-0103. PMID 16002463.
External links[edit]